🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent/ Metastatic NPC

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC NCT06657690Phase 21 site📍 Zhuhai Sun Yat-sen University · Tests: Irinotecan liposome, S-1 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma NCT06976190Phase 31 site📍 Guangzhou Lepu Biopharma Co., Ltd. · Tests: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemoradiotherapy combined with immunotherapy Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) NCT06241599Phase 2, Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: GP/PFLL+AK104, GP/PFLL+placebo SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma NCT06323239Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: SBRT, Low-dose Radiotherapy (LDRT), Toripalimab, Gemcitabine, Cisplatin JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma NCT07690787Phase 21 site📍 Hong Kong Chinese University of Hong Kong · Tests: JS207, Paclitaxel, Capecitabine Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants NCT00898638n/a4 sites📍 Nashville📍 Nashville📍 Nashville Vanderbilt University Medical Center · Tests: biologic sample preservation procedure, medical chart review Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors NCT07625423Phase 11 site📍 Chengdu West China Hospital · Tests: EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" NCT01365169NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Exercise Intervention, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma NCT06194656Phase 22 sites📍 Shanghai📍 Shanghai Shanghai Institute Of Biological Products · Tests: HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclona… Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC NCT06472713Phase 21 site📍 Zhuhai Ming-Yuan Chen · Tests: Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy NCT06676722Phase 22 sites📍 Xiamen📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: SBRT combined with Nimotuzumab followed by Tislelizumab Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial NCT07070479Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ming-Yuan Chen · Tests: Ivonescimab, Nimotuzumab, Irinotecan liposome, S-1, Mitoxantrone Hydrochloride Liposome Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270Phase 295 sites📍 Dublin📍 Fremont📍 Fresno National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC NCT07325539Phase 22 sites📍 Guangzhou📍 Shenzhen Sun Yat-sen University · Tests: Gemcitabine(GEM), Cisplatin, Toripalimab, LDRT A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06437522Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 monoclonal antibody Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation NCT06662058NA1 site📍 Atlanta Emory University · Tests: Audiometric Test, Audiometric Test, Audiometric Test, Interview A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy NCT06839066Phase 215 sites📍 Fuzhou📍 Dongguan📍 Guangzhou Shanghai Henlius Biotech · Tests: HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3 Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma NCT06669611Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Camrelizumab combined GP chemotherapy, Camrelizumab combined TPC chemotherapy A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. NCT07258979Phase 1, Phase 220 sites📍 Chongqing📍 Fuzhou📍 Xiamen MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL201, Toripalimab, Cisplatin Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial NCT07101744Phase 21 site📍 Guangdong Sun Yat-sen University · Tests: Iparomlimab and Tuvonralimab Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Camrelizumab, Gemcitabine, Cisplatin, Apatinib Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial NCT06636734Phase 22 sites📍 Atlanta📍 Atlanta Emory University · Tests: Biospecimen Collection, Computed Tomography, Lovastatin, Magnetic Resonance Imaging, Pembrolizumab Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma NCT07581821Phase 21 site📍 Zhuhai Ming-Yuan Chen · Tests: Sintilimab + Anlotinib + taxane-based chemotherapy A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer NCT06457503Phase 413 sites📍 Little Rock📍 Irvine📍 San Francisco Coherus Oncology, Inc. · Tests: Toripalimab, Cisplatin, Gemcitabine, Carboplatin Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma NCT06509009Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nimotuzumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy